Evidence map›Paper›PMID 40821704›Full record

ArticleCancer management and research2025

The Chemotherapy Medication of

Jingkun Chen, Xiaohui Zheng, Xiaobing Wang, Ching-Feng Weng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jingkun ChenDepartment of Stomatology, Zhongshan Hospital Affiliated with Xiamen University, Xiamen, 361004, People's Republic of China.
Xiaohui ZhengDepartment of Physiology, School of Basic Medical Sciences, Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Xiamen, 361023, People's Republic of China.
Xiaobing WangDepartment of Pharmacy, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, 361004, People's Republic of China.
Ching-Feng WengDepartment of Physiology, School of Basic Medical Sciences, Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Xiamen, 361023, People's Republic of China.ORCID 0000-0002-9747-8697

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Oral tongue squamous cell carcinoma (OTSCC), the most prevalent oral malignancy, lacks effective treatments. Objective: Evaluate Evodia lepta ( Methods: Cell viability (CCK-8) and protein expression (Western blot) were assessed in OTSCC (CAL27, TCA8113) and 3T3 cells after 24h treatment with Results: Cisplatin significantly reduced the viability in all cells (IC Conclusion:

Indexed as

cisplatincytotoxicityEvodia leptamechanismtongue cancer

Identifiers

PMID40821704
PMCPMC12357569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.